Bleomycin (Blenoxane) — Clinical FAQs

Question 1

What is Bleomycin FDA-approved to treat?

Accepted Answer

Bleomycin is FDA-approved for the following oncology indications: 1. Squamous cell carcinoma (head and neck, esophagus, skin, penis, cervix, vulva) 2. Testicular carcinoma (non-seminomatous and seminomatous germ cell tumors) 3. Hodgkin lymphoma (component of ABVD regimen) 4. Non-Hodgkin lymphoma 5. Malignant pleural effusion (sclerosing agent for pleurodesis).

Question 2

How does Bleomycin work (mechanism of action)?

Accepted Answer

Bleomycin is a glycopeptide antitumor antibiotic that exerts its cytotoxic effect primarily through DNA strand scission. It chelates ferrous iron (Fe²⁺) and reacts with molecular oxygen to generate reactive oxygen species — principally superoxide and hydroxyl radicals — that cleave both single-stranded and double-stranded DNA at specific G-C and G-T sequences. Because bleomycin's cytotoxicity is not dependent on active DNA synthesis, it is cell-cycle active principally in the G2 and M phases. Uniquely, bleomycin causes minimal myelosuppression because bone marrow cells express high levels of bleomycin hydrolase, the inactivating enzyme; tissues with low hydrolase activity (lung, skin) are preferentially susceptible to toxicity.

Question 3

How is Bleomycin administered?

Accepted Answer

Bleomycin is administered Intravenous (IV) or Intramuscular (IM) or Subcutaneous (SC) or Intravesical. Administer a test dose of 1–2 units IM or IV before the first full dose in lymphoma patients to detect idiosyncratic anaphylactoid reactions; observe for at least 1 hour.

Question 4

What are the most common side effects of Bleomycin?

Accepted Answer

The most commonly reported side effects of Bleomycin (≥10% incidence) include: Fever and chills (very common; occurs in up to 60% of patients, usually 4–10 hours post-dose), Skin toxicity: hyperpigmentation, hyperkeratosis, erythema, skin thickening, striae, peeling (particularly over pressure areas, elbows, and fingernails), Mucosal toxicity: stomatitis, mucositis, Alopecia (mild to moderate), Nail changes (banding, ridging) and others (9 total). Consult your oncologist for complete prescribing information.

Question 5

Does Bleomycin have a black box warning?

Accepted Answer

Yes. Bleomycin carries FDA black box warning(s) regarding: 1. Pulmonary toxicity: Bleomycin causes pulmonary fibrosis, which is the most severe and potentially fatal toxicity. Pulmonary toxicity occurs in approximately 10% of patients and is fatal in approximately 1%. Risk is increased with cumulative doses exceeding 400 units, age >70 years, prior thoracic radiation, concomitant oxygen administration, and renal insufficiency. Manifestations include subacute pneumonitis progressing to fibrosis. Assess pulmonary function regularly during therapy; discontinue immediately if pulmonary toxicity develops. 2. Idiosyncratic reactions: Severe anaphylactoid reactions, including hypotension, fever, chills, mental confusion, and wheezing, have been reported in approximately 1% of lymphoma patients. A test dose of 1–2 units should be administered prior to the first dose; resuscitative equipment must be immediately available.

Question 6

Is Bleomycin safe during pregnancy?

Accepted Answer

Bleomycin pregnancy safety: Category D — Bleomycin causes fetal harm. Animal studies demonstrate embryotoxicity and teratogenicity. The drug is used in ABVD and BEP regimens in young patients of reproductive age; effective contraception is mandatory during therapy. Breastfeeding should be discontinued during treatment.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Bleomycin — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms